Physician profile
Christopher Ryan Mitchell
NPI 1124274105
$18,815.96
in general payments reported to CMS, 2019-2025
35 companies · $2,590 in 2025
The $2,590 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $2,971 · 2021: $4,520 · 2022: $1,272 · 2023: $1,865 · 2024: $4,407 · 2025: $2,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,197 · Food and Beverage: $2,220 · Consulting Fee: $1,410 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,197.36 |
| Food and Beverage | $2,219.88 |
| Consulting Fee | $1,410.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,197.36 | 2023-2024 | Da Vinci Surgical System |
| Richard Wolf Medical Instruments Corp. | $4,134.18 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,712.34 | 2020-2025 | Imfinzi, Lynparza |
| Janssen Scientific Affairs, LLC | $1,555.05 | 2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $1,375.11 | 2020-2024 | Provenge |
| Neotract INC. | $1,041.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $944.48 | 2022 | |
| Urogen Pharma, INC. | $720.50 | 2020-2025 | |
| Janssen Biotech, INC. | $218.22 | 2021-2025 | Erleada |
| Pfizer INC. | $212.22 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $170.07 | 2021-2025 | Keytruda, Lynparza |
| Myriad Genetic Laboratories, INC. | $155.62 | 2021 | |
| Telix Pharmaceuticals | $153.44 | 2023-2025 | Illuccix |
| Tolmar, INC. | $151.45 | 2024 | |
| Ferring Pharmaceuticals INC. | $131.25 | 2025 | Adstiladrin |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $107.54 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $98.22 | 2023-2024 | Pylarify |
| Baxter Healthcare | $97.20 | 2023-2024 | Tisseel |
| Palette Life Sciences, INC. | $84.20 | 2022 | |
| Astellas Pharma US INC | $67.57 | 2022-2023 | Xtandi |
| Tempus Ai, INC | $56.98 | 2025 | Xt Cdx |
| Civco Medical Instruments | $54.28 | 2025 | |
| Novartis Pharmaceuticals Corporation | $48.72 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $44.27 | 2025 | Orgovyx |
| Dentsply Ih Ab | $42.89 | 2023 | Lofric |
| Abbvie INC. | $36.36 | 2021-2022 | |
| Verity Pharmaceuticals INC. | $31.92 | 2022-2023 | Trelstar |
| Axonics, INC. | $31.24 | 2023 | Axonics |
| Blue Earth Diagnostics | $26.50 | 2025 | Posluma |
| Allergan, INC. | $24.50 | 2021 | |
| Ethicon US, LLC | $24.44 | 2025 | Echelon; Endopath |
| Becton, Dickinson and Company | $22.89 | 2019 | |
| Koelis INC. | $15.27 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2022 | |
| Photocure INC | $13.77 | 2023 | Cysview |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.